Karlowsky J A, Zhanel G G, Klym K A, Hoban D J, Kabani A M
Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada.
Diagn Microbiol Infect Dis. 1997 Sep;29(1):5-9. doi: 10.1016/s0732-8893(97)00068-0.
The incidence of candidemia was reviewed at the Health Sciences Centre in Winnipeg, Canada, over a 21-year period (1976 to 1996). Candida species were identified as blood-stream isolates in significantly (p < 0.05) higher numbers from 1991 to 1996 than in the previous 15 years. Antifungal susceptibilities remained unchanged with Candida albicans isolates tested from 1985 to 1996. Retrospective chart reviews revealed that all patients with candidemia possessed at least two risk factors. The main risk factors identified were recent or concurrent antibiotic therapy (95% of patients), presence of a central line (93% of patients), and immunosuppression (88% of patients). Treatment generally involved amphotericin B therapy (81% of patients), and death occurred in 52% of the patients. Mortality directly attributable to Candida species could be established in 23% of patients.
对加拿大温尼伯市健康科学中心21年期间（1976年至1996年）念珠菌血症的发病率进行了回顾性研究。1991年至1996年期间，念珠菌属作为血流分离株被鉴定出的数量显著（p<0.05）高于此前15年。1985年至1996年对白色念珠菌分离株进行的抗真菌药敏试验结果未发生变化。回顾性病历审查显示，所有念珠菌血症患者均至少有两个危险因素。确定的主要危险因素为近期或同时进行抗生素治疗（95%的患者）、存在中心静脉导管（93%的患者）和免疫抑制（88%的患者）。治疗通常采用两性霉素B治疗（81%的患者），52%的患者死亡。23%的患者可确定念珠菌属直接导致了死亡。
